Why Horizon Pharmaceuticals (HZNP) Is Plummeting Today

NEW YORK (TheStreet) -- Horizon Pharmaceuticals  (HZNP) plummeted Monday after the company said CVS Caremark  (CVS) and Express Scripts  (ESRX) would put Horizon's two best-selling drugs on their exclusion lists at the beginning of 2015.

The move to the exclusion list means patients would incur more of a cost for the drugs unless they switch to cheaper alternatives. CVS and Express Scripts are the largest and second-largest pharmacy benefit managers in the U.S.

The two drugs are Duexis, which treats arthritis pains for those with stomach issues, and Vimovo, which treats osteoporosis and rheumatoid arthritis. Horizon acquired the U.S. rights to Vimovo from AstraZeneca  (AZN) in November.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Horizon, which disclosed the news in a regulatory filing, said the exclusions should not affect 2014 guidance but said nothing about next year; however, the company noted 20% to 30% of Duexis and Vimovo prescriptions could be affected.

For more on this story, read TheStreet's Adam Feuerstein's article here.

The stock was down 33.74% to $9.21 at 2:23 p.m. More than 11.8 million shares had changed hands, compared to the average volume of 2,857,670.

HZNP Chart HZNP data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

P&G, GE and IBM Need to Innovate; Has Starbucks' Stock Grown Ice Cold?--ICYMI

P&G, GE and IBM Need to Innovate; Has Starbucks' Stock Grown Ice Cold?--ICYMI

Is Best Buy Sleeping With the Enemy With Amazon Partnership?

Is Best Buy Sleeping With the Enemy With Amazon Partnership?

Sprint, T-Mobile Might Have to Do More Than Make Promises to Get Deal Approved

Sprint, T-Mobile Might Have to Do More Than Make Promises to Get Deal Approved

Video: The S&P 500 Is Failing to Make New Highs

Video: The S&P 500 Is Failing to Make New Highs

Dow, S&P 500 and Nasdaq Finish Lower as Apple, P&G Slump

Dow, S&P 500 and Nasdaq Finish Lower as Apple, P&G Slump